Overview
Venue and Accommodations
Learning Objectives
Agenda
Faculty
Online Registration Form
Fax Registration Form
      Program Overview  
   

OVERVIEW
6th Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia

Program Director: Fredrick Hagemeister, MD, Internist and Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

July 15, 2017- Houston Marriott at the Texas Medical Center, 6580 Fannin Street, Houston, TX 77030; Phone: 713-796-0080

Jointly Provided by
The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health

Educational Grants

Amgen Inc.
Merck Sharp & Dohme Corp.
AbbVie Inc.
Gilead Sciences Inc.
Novartis Pharmaceuticals Corporation
Pfizer
Millennium Pharmaceuticals, Inc.

For online registration and more information visit: www.cancernetus.com

Target Audience

This symposium is directed primarily to hematologists/oncologists, radiation oncologists, researchers, pharmacists, registered nurses, physician assistants, nurse practitioners and fellows in training interested in new development in lung cancer. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

Statement of Need/Program Overview

This symposiumis intended to improve care ofpatients with Hodgkins lymphoma, B-cell lymphoma, multiple myeloma and leukemiaby accelerating adoption of new guidelines and evidence-based practice change. The format will include didactic lectures from knownopinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

Learning Objectives

  • Evaluate the prognostic markers, risk stratification and the impact on novel therapies for Hodgkin lymphoma
  • Interpret and adapt the data from recent clinical trials on immunotherapy options for Hodgkin lymphoma
  • Identify the treatment options for diffuse large B-cell lymphoma (DLBCL)
  • Cite the treatment options for follicular lymphoma (FL)
  • Apply the treatment options for chronic lymphocytic lymphoma (CLL)
  • Identify the treatment options for mantle cell lymphoma (MCL)
  • Identify benefit and risks of available immunomodulatory agents, proteasome inhibitors or both as systemic therapy for patients with newly diagnosed active multiple myeloma (MM)
  • Evaluate available data on the selection, sequencing and/or combination of novel therapeutic agents in the treatment of patients with relapsed/refractory MM
  • Evaluate the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with acute lymphoblastic leukemia (ALL)
  • Evaluate the gene–gene co-occurrences and how compound genotypes are related to novel therapeutic options based clinical outcomes in patients with acute myeloid leukemia (AML)
  • Identify response assessment and management of tyrosine kinase inhibitors resistance in the treatment of chronic myelogenous leukemia (CML)
  • Discuss the time-based response milestones and monitoring in patients with CML

Faculty
Jorge Cortes, MD, Professor and Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center Houston, TX

Nathan Fowler, MD, Associate Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Fredrick B. Hagemeister, MD, Internist and Professor of Medicine, Department of Lymphoma/ Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Elias Jabbour, MD, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Elisabet E. Manasanch, MD,Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Robert Orlowski, MD, PhD,Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Michael Wang, MD, Professor of Medicine, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX    

William G. Wierda, MD, Professor of Medicine, Department of Lymphoma/ Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX

 

Registration Fee
Registration fee partially covers continental breakfast, lunch and syllabus book

 
Early Registration Fee
(Up to June30, 2017)
Discounted Registration Fee
(July 01 - 07, 2017)

Regular Registration Fee
(July 08 - 15, 2017)

Physicians
$100.00
$130.00
$160.00
Registered Nurses
$75.00
$95.00
$115.00
Nurse Practitioners
$75.00
$95.00
$115.00
Physician Assistants
$75.00
$95.00
$115.00
Pharmacists
$75.00
$95.00
$115.00
Fellows
$75.00
$95.00
$115.00
*Industry
$350.00
$400.00
$450.00
*Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

Payment may be made: MC Visa Discover Check
Credit Card Number___________________________ Expiration Date_______________
Name and address________________________________________________________
________________________________________________________________________
________________________________________________________________________
Signature________________________________________________________________
as given on the monthly credit card statement
No refund. Substitution is allowed.

Please make checks payable to CancerNet. Mail checks to CancerNet, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057

To reserve your place for the meeting, please complete the registration form and fax it 443-267-0016. For questions if any please call Brian Waggoner at 972-459-5222 or E-mail: brianw@cancernetus.com

Physician Continuing Education

Accreditation Statement

This activity has been planned and implemented in accordance with the essential areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health and CancerNet. The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this educational activity for a maximum of 6.25 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Accreditation Statement
American Health Resources, Inc. is approved by the California Board of Registered Nursing, Provider # CEP 14254 and approved this program for 6.25 contact hours. Please check with licensing board to verify credits can be claimed in your state.

Pharmacist Continuing Education
Accreditation Statement
temp American Health Resource is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity provides 6.25 contact hours (0.625 CEUs) - Knowledge based credits
ACPE Universal Activity Number: 0280-9999-16-051-L01-P
Participant Requirements (Nurses and Pharmacists) for Credit:

  • Participants must fully attend all sessions as well as pass in a completed signature verification form (No partial credit will be given).
  • Participants can earn Continuing Education credits for this program by logging onto the website https://ce.ahrevents.com/ and completing the session evaluation form using access code provided.
  • Nurses: After completion of the evaluation, certificate of credit can be printed.
  • Pharmacists: After completion of the activity evaluation, pharmacy education credit is automatically reported to CPE Monitor where a certificate of credit can be printed. Please allow up to 48 hours for credit to be available on the CPE Monitor.

*Only Certificates of Credit issued from CPE Monitor are valid in the US
* CPE Monitor will not accept credits after 60 days from the session date

  • All participant names will be checked against program attendance sheets for verification of attendance.

Disclosure & Evaluation:
All participants will have the opportunity to evaluate the educational session and presenter as well as the ability to identify their future educational needs. Disclosure will be made on the day of the program regarding any interest or affiliation a speaker may have with a supporting organization.

 

 
             


Home    |     Live Events    |     Webcasts    |     About CancerNet    |     Contact Us

Copyright © 2012 Cancernet. All rights reserved.